share_log

科倫博泰生物(06990.HK)治療晚期實體瘤新藥獲批臨床試驗

Cullen Biotec (06990.HK) has been approved for clinical trials of a new drug for the treatment of advanced solid tumors.

AASTOCKS ·  Jun 17 16:46

Coronbio-Tech-B (06990.HK) announced that on June 17th (today), it received the clinical trial notice of SKB518, an innovative drug injection developed by the company, approved by the drug evaluation center of the National Pharmaceutical Administration.

SKB518, an injection, is an innovative antibody drug developed by the company using the OptiDC platform technology based on the characteristics of target biology. It has shown good efficacy and safety in preclinical studies and is intended for the treatment of advanced solid tumors.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment